UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 14, 2023
Semper
Paratus Acquisition Corporation
(Exact
name of registrant as specified in its charter)
| Cayman
Islands |
|
001-41002 |
|
N/A |
(State
or Other Jurisdiction
of
Incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
767
Third Avenue, 38th Floor
New
York, New York 10017
(Address
of Principal Executive Offices) (Zip Code)
(646)
807-8832
(Registrant’s
Telephone Number, Including Area Code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☒ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of Each Class |
|
Trading
Symbol(s) |
|
Name
of Each Exchange on Which Registered |
| Units, each consisting
of one Class A ordinary share, par value $0.0001 per share, and one-half of one Redeemable Warrant |
|
LGSTU |
|
The Nasdaq Stock Market
LLC |
| Class A ordinary shares,
par value $0.0001 per share, included as part of the Units |
|
LGST |
|
The Nasdaq Stock Market
LLC |
| Redeemable warrants, each
exercisable for one Class A ordinary share for $11.50 per share, included as part of the Units |
|
LGSTW |
|
The Nasdaq Stock Market
LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
7.01. Regulation FD Disclosure.
As
previously disclosed, on June 28, 2023, Semper Paratus Acquisition Corporation, a Cayman Island exempted company (“Semper Paratus”)
entered into an Agreement and Plan of Merger by and among Semper Paratus, Semper Merger Sub, Inc., a Delaware corporation and a wholly
owned subsidiary of Semper Paratus (“Merger Sub”), SSVK Associates, LLC, Semper Paratus’ sponsor, in its capacity as
purchaser representative, Tevogen Bio Inc, a Delaware corporation (“Tevogen Bio”), and Ryan Saadi, in his capacity as seller
representative (as may be amended and/or restated from time to time, the “Merger Agreement”), pursuant to which, among other
things, the parties will effect the merger of Merger Sub with and into Tevogen Bio, with Tevogen Bio continuing as the surviving entity
(the “Merger”), as a result of which all of the issued and outstanding capital stock of Tevogen Bio shall be exchanged for
shares of Class A common stock, par value $0.0001 per share, of Semper Paratus (the “Share Exchange”), subject to the conditions
set forth in the merger Agreement, with Tevogen Bio surviving the Share Exchange as a wholly owned subsidiary of Semper Paratus (the
Merger, the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the “Transaction”).
On
September 14, 2023, Semper Paratus issued a press release announcing that it had filed a Registration Statement on Form S-4. A
copy of the press release is attached hereto as Exhibit 99.1.
The
information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liabilities under that
section, and shall not be deemed to be incorporated by reference into the filings of Semper Paratus under the Securities Act of 1933,
as amended (the “Securities Act”) or the Exchange Act, regardless of any general incorporation language in such filings.
For the avoidance of doubt, Semper Paratus intends for this Form 8-K, including Exhibit 99.1, to satisfy the requirements of Rule 165(a)
and Rule 425(a) under the Securities Act. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any
information in this Item 7.01, including Exhibit 99.1.
Forward-Looking
Statements
This
Current Report on Form 8-K contains certain statements that are not historical facts and are forward-looking statements within the meaning
of the federal securities laws with respect to the proposed Transaction between Semper Paratus and Tevogen Bio, including without limitation
statements regarding the anticipated benefits of the proposed Transaction, the anticipated timing of the proposed Transaction, the implied
enterprise value, future financial condition and performance of Tevogen Bio and the combined company after the closing and expected financial
impacts of the proposed Transaction, the satisfaction of closing conditions to the proposed Transaction, the level of redemptions of
Semper Paratus’ public shareholders and the product candidates, products, markets, and expected future performance and market opportunities
of Tevogen Bio. These forward-looking statements generally are identified by the words “believe,” “project,”
“expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,”
“future,” “opportunity,” “potential,” “plan,” “seeks,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking
statements are predictions, projections and other statements about future events that are based on current expectations and assumptions
and, as a result, are subject to risks and uncertainties.
These
forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as,
a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult
or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the
forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed Transaction may not be
completed in a timely manner or at all, which may adversely affect the price of Semper Paratus’ securities; (ii) the risk that
the proposed Transaction may not be completed by Semper Paratus’ business combination deadline; (iii) the failure to satisfy the
conditions to the consummation of the proposed Transaction, including the approval of the Merger Agreement by the shareholders of Semper
Paratus, the satisfaction of the minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party
approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement;
(v) the failure to achieve the minimum amount of cash available following any redemptions by Semper Paratus’ shareholders; (vi)
redemptions exceeding anticipated levels or the failure to meet NYSE initial listing standards in connection with the consummation of
the proposed Transaction; (vii) the effect of the announcement or pendency of the proposed Transaction on Tevogen Bio’s business
relationships, operating results, and business generally; (viii) risks that the proposed Transaction disrupts current plans and operations
of Tevogen Bio; (ix) the outcome of any legal proceedings that may be instituted against Tevogen Bio or against Semper Paratus related
to the Merger Agreement or the proposed Transaction ; (x) changes in the markets in which Tevogen Bio competes, including with respect
to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions;
(xii) risk that Tevogen Bio may not be able to execute its growth strategies; (xiii) risks related to the ongoing COVID-19 pandemic and
response, including supply chain disruptions; (xiv) risk that Tevogen Bio may not be able to develop and maintain effective internal
controls; (xv) costs related to the proposed Transaction and the failure to realize anticipated benefits of the proposed Transaction
or to realize estimated pro forma results and underlying assumptions, including with respect to estimated shareholder redemptions; (xvi)
the ability to recognize the anticipated benefits of the proposed Transaction and to achieve its commercialization and development plans,
and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen
Bio to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Tevogen Bio may fail to keep pace
with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful
new products and services; (xviii) the ability to develop, license or acquire new therapeutics; (xix) the risk that Tevogen Bio will
need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xx) the risk
that Tevogen Bio, post-combination, experiences difficulties in managing its growth and expanding operations; (xxi) the risk of product
liability or regulatory lawsuits or proceedings relating to Tevogen Bio’s business; (xxii) uncertainties inherent in the execution,
cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development;
(xxiii) risks associated with intellectual property protection; (xxiv) the risk that Tevogen Bio is unable to secure or protect its intellectual
property; (xxv) Tevogen Bio’s limited operating history; and (xxvi) those factors discussed in Semper Paratus’ filings with
the SEC and that that will be contained in the proxy statement/prospectus relating to the proposed Transaction.
The
foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties
that will be described in the “Risk Factors” section of the preliminary proxy statement/prospectus and the amendments thereto,
the definitive proxy statement/prospectus, and other documents to be filed by Semper Paratus from time to time with the SEC. These filings
identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those
contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned
not to put undue reliance on forward-looking statements, and while Tevogen Bio and Semper Paratus may elect to update these forward-looking
statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise, except as required by applicable law. Neither of Tevogen Bio or Semper Paratus
gives any assurance that Tevogen Bio or Semper Paratus, or the combined company, will achieve its expectations. These forward-looking
statements should not be relied upon as representing Semper Paratus’ or Tevogen Bio’s assessments as of any date subsequent
to the date of this Current Report. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Additional
Information and Where to Find It
In
connection with the Merger Agreement and the proposed Transaction, Semper Paratus has filed materials with the Securities and Exchange
Commission (the “SEC”), including a registration statement on Form S-4 (the “Form S-4”), which includes a preliminary
proxy statement/prospectus of Semper Paratus, and will file other documents regarding the proposed transaction with the SEC. This communication
is not intended to be, and is not, a substitute for the proxy statement/prospectus or any other document that Semper Paratus has filed
or may file with the SEC in connection with the proposed transaction. The Company’s shareholders and other interested persons are
advised to read the Form S-4, the preliminary proxy statement/prospectus and the amendments thereto, the definitive proxy statement/prospectus
and documents incorporated by reference therein filed in connection with the proposed Transaction, as these materials will contain important
information about Semper Paratus, Tevogen Bio, the Merger Agreement, and the proposed Transaction. When available, the definitive proxy
statement/prospectus and other relevant materials for the proposed Transaction will be mailed to shareholders of Semper Paratus as of
a record date to be established for voting on the proposed Transaction. Before making any voting or investment decision, investors and
shareholders of Semper Paratus are urged to carefully read the entire proxy statement/prospectus and any other relevant documents filed
with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the
proposed Transaction. The Company’s investors and shareholders will also be able to obtain copies of the preliminary proxy statement/prospectus,
the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without
charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Semper Paratus Acquisition Corporation,
767 Third Avenue, 38th Floor, New York, NY, 10017, Attention: Mr. Suren Ajjarapu.
Participants
in the Solicitation
Semper
Paratus, Tevogen Bio, and their respective directors, executive officers, other members of management and employees may be deemed participants
in the solicitation of proxies from Semper Paratus’ shareholders with respect to the proposed Transaction. Investors and security
holders may obtain more detailed information regarding the names and interests in the proposed Transaction of Semper Paratus’ directors
and officers in Semper Paratus’ filings with the SEC, including the Form S-4, the preliminary proxy statement/prospectus and the
amendments thereto, the definitive proxy statement/prospectus, and other documents filed with the SEC. Such information with respect
to Tevogen Bio’s directors and executive officers will also be included in the proxy statement/prospectus.
No
Offer or Solicitation
This
Current Report on Form 8-K is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of
the proposed Transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there
be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus
meeting the requirements of the Securities Act.
Item
9.01. Financial Statements and Exhibits.
The
following exhibits are being filed herewith:
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
SEMPER PARATUS ACQUISITION CORP. |
| |
|
|
| Date:
September 14, 2023 |
By: |
/s/
Surendra Ajjarapu |
| |
|
Name: Surendra Ajjarapu |
| |
|
Title: Chief Executive Officer |
Exhibit
99.1
Semper
Paratus Acquisition Corporation Files Registration Statement on Form S-4 in Connection with Proposed Business Combination with Tevogen
Bio Inc
New
York, NY, September 14, 2023 (GLOBE NEWSWIRE) – Semper Paratus Acquisition Corporation (Nasdaq: LGST) (“Semper Paratus”),
a publicly traded special purpose acquisition company, today announced the filing of a registration statement on Form S-4 (the “Registration
Statement”) with the U.S. Securities and Exchange Commission relating to Semper Paratus’ previously announced proposed business
combination with Tevogen Bio Inc, a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified
T cell therapeutics in virology, oncology, and neurology.
The
Registration Statement contains a preliminary proxy statement and prospectus in connection with the previously announced agreement and
plan of merger (the “Merger Agreement”) and proposed business combination between Semper Paratus and Tevogen Bio (the “Transaction”).
While the Registration Statement has not yet become effective and the information contained therein is subject to change, it provides
important information about Tevogen Bio, Semper Paratus, and the Transaction. Upon closing of the Transaction, the combined company will
be named Tevogen Bio Holdings Inc. (“Tevogen Holdings”). Tevogen Holdings common stock and warrants are expected to be listed
on NYSE American under the new ticker symbols “TVGN” and “TVGNW”, respectively.
The
Transaction, which has been approved by the boards of directors of Tevogen Bio and Semper Paratus, is expected to close near the end
of 2023, subject to, among other things, SEC review, approval by Semper Paratus shareholders, regulatory approvals, and the satisfaction
of other customary closing conditions.
Ryan
Saadi, CEO of Tevogen Bio, remarked, “I congratulate both our dedicated team and our valued partners for achieving this significant
milestone in such a short time. This is a testament to each member’s commitment to Tevogen’s patient-centric approach of merging affordability
with advanced science — a blueprint for sustainable success in the upcoming era of medicine.”
Tevogen
Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic
T lymphocytes, to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological
disorders with the aim of addressing the significant unmet needs of large patient populations. Tevogen Bio believes that sustainability
and commercial success in the forthcoming era of medicine will rely on ensuring patient accessibility through advanced science and innovative
business models. Tevogen Bio aspires to be the first biotechnology company offering commercially attractive, economically viable, and
cost-effective personalized T cell therapies.
About
Tevogen Bio
Tevogen
Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product
launch experience. Tevogen Bio’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine,
and that disruptive business models are required to sustain medical innovation in the post-pandemic world.
About
Semper Paratus
Semper
Paratus is a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition,
stock purchase, reorganization, or similar business combination with one or more businesses. Its principals possess public and private
market investing experience and operational knowledge to bring value added benefits to Tevogen Bio. The Semper Paratus team has substantial
experience investing in and operating businesses in multiple sectors, as well as a significant long-term track record in creatively structuring
transactions to unlock and maximize value.
Forward-Looking
Statements
This
press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the
federal securities laws with respect to the Transaction between Semper Paratus and Tevogen Bio, including without limitation statements
regarding the anticipated benefits of the Transaction, the anticipated timing of the Transaction, the implied enterprise value, future
financial condition and performance of Tevogen Bio and the combined company after the closing and expected financial impacts of the Transaction,
the satisfaction of closing conditions to the Transaction, the level of redemptions of Semper Paratus’ public stockholders and
the product candidates, products, markets, and expected future performance and market opportunities of Tevogen Bio. These forward-looking
statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,”
“estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,”
“potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,”
“will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these
words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements
about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.
These
forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as,
a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult
or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the
forward-looking statements in this communication, including but not limited to: (i) the risk that the Transaction may not be completed
in a timely manner or at all, which may adversely affect the price of Semper Paratus’ securities; (ii) the risk that the Transaction
may not be completed by Semper Paratus’ business combination deadline; (iii) the failure to satisfy the conditions to the consummation
of the Transaction, including the approval of the Merger Agreement by the stockholders of Semper Paratus, the satisfaction of the minimum
cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any
event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum
amount of cash available following any redemptions by Semper Paratus’ stockholders; (vi) redemptions exceeding anticipated levels
or the failure to meet NYSE initial listing standards in connection with the consummation of the Transaction; (vii) the effect of the
announcement or pendency of the Transaction on Tevogen Bio’s business relationships, operating results, and business generally;
(viii) risks that the Transaction disrupts current plans and operations of Tevogen Bio; (ix) the outcome of any legal proceedings that
may be instituted against Tevogen Bio or against Semper Paratus related to the Merger Agreement or the Transaction ; (x) changes in the
markets in which Tevogen Bio competes, including with respect to its competitive landscape, technology evolution, or regulatory changes;
(xi) changes in domestic and global general economic conditions; (xii) the risk that Tevogen Bio may not be able to execute its growth
strategies; (xiii) risks related to the COVID-19 pandemic and response, including supply chain disruptions; (xiv) risk that Tevogen Bio
may not be able to develop and maintain effective internal controls; (xv) costs related to the Transaction and the failure to realize
anticipated benefits of the Transaction or to realize estimated pro forma results and underlying assumptions, including with respect
to estimated stockholder redemptions; (xvi) the ability to recognize the anticipated benefits of the Transaction and to achieve its commercialization
and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition,
the ability of Tevogen Bio to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Tevogen Bio
may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments
in unsuccessful new products and services; (xviii) risks related to the ability to develop, license or acquire new therapeutics; (xix)
the risk that Tevogen Bio will need to raise additional capital to execute its business plan, which may not be available on acceptable
terms or at all; (xx) the risk that Tevogen Bio, post-combination, experiences difficulties in managing its growth and expanding operations;
(xxi) the risk of product liability or regulatory lawsuits or proceedings relating to Tevogen Bio’s business; (xxii) uncertainties
inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval
and commercial development; (xxiii) risks associated with intellectual property protection; (xxiv) the risk that Tevogen Bio is unable
to secure or protect its intellectual property; and (xxv) Tevogen Bio’s limited operating history; (xxvi) uncertainties inherent
in the execution, cost, and completion of preclinical studies and clinical trials; (xxvii) risks related to regulatory review and approval
and commercial development; and (xxviii) those factors discussed in Semper Paratus’ filings with the SEC and that that will be
contained in the proxy statement/prospectus relating to the Transaction.
The
foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties
that will be described in the “Risk Factors” section of the proxy statement/prospectus and the amendments thereto, the definitive
proxy statement/prospectus, and other documents to be filed by Semper Paratus from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained
in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and while Tevogen Bio and Semper Paratus may elect to update these forward-looking statements
at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by applicable law. Neither of Tevogen Bio or Semper Paratus gives any assurance
that Tevogen Bio or Semper Paratus, or the combined company, will achieve its expectations. These forward-looking statements should not
be relied upon as representing Semper Paratus’ or Tevogen Bio’s assessments as of any date subsequent to the date of this
press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Additional
Information and Where to Find It
In
connection with the Merger Agreement and the Transaction, Semper Paratus has filed relevant materials with the Securities and Exchange
Commission, including a registration statement on Form S-4, which includes a preliminary proxy statement/prospectus of Semper Paratus,
and will file other documents regarding the Transaction with the SEC. This communication is not intended to be, and is not, a substitute
for the proxy statement/prospectus or any other document that Semper Paratus has filed or may file with the SEC in connection with the
Transaction. When available, the definitive proxy statement and other relevant materials for the Transaction will be mailed or made available
to stockholders of Semper Paratus as of a record date to be established for voting on the Transaction. Before making any voting or investment
decision, investors and stockholders of Semper Paratus are urged to carefully read, when they become available, the entire registration
statement, the proxy statement/prospectus, and any other relevant documents filed with the SEC, as well as any amendments or supplements
to these documents, and the documents incorporated by reference therein, because they will contain important information about Semper
Paratus, Tevogen Bio, and the Transaction. Semper Paratus’ investors and stockholders and other interested persons will also be
able to obtain copies of the registration statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus,
other documents filed with the SEC that will be incorporated by reference therein, and all other relevant documents filed with the SEC
by Semper Paratus in connection with the Transaction, without charge, once available, at the SEC’s website at www.sec.gov, or by
directing a request to: Semper Paratus Acquisition Corporation, 767 Third Avenue, 38th Floor, New York, NY 10017, Attention: Mr. Suren
Ajjarapu.
Participants
in the Solicitation
Semper
Paratus, Tevogen Bio, and their respective directors, executive officers, other members of management and employees may be deemed participants
in the solicitation of proxies from Semper Paratus’ stockholders with respect to the Transaction. Investors and security holders
may obtain more detailed information regarding the names and interests in the Transaction of Semper Paratus’ directors and officers
in Semper Paratus’ filings with the SEC, including the Form S-4, the preliminary proxy statement/prospectus, when filed with the
SEC, the definitive proxy statement/prospectus, amendments and supplements thereto, and other documents filed with the SEC. Such information
with respect to Tevogen Bio’s directors and executive officers will also be included in the proxy statement/prospectus. You may
obtain free copies of these documents as described in the preceding paragraph.
No
Offer or Solicitation
This
press release is not a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the Transaction
and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities
in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements
of the Securities Act of 1933, as amended.
Contacts
Tevogen
Communications
T:
1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
Semper
Paratus Acquisition Corporation
suren@semperparatusspac.com
Semper Paratus Acquisiti... (NASDAQ:LGSTU)
過去 株価チャート
から 5 2024 まで 6 2024
Semper Paratus Acquisiti... (NASDAQ:LGSTU)
過去 株価チャート
から 6 2023 まで 6 2024
